| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
35,410,000 |
| Market
Cap: |
693.33(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$13.21 - $21.74 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Kiniksa Pharmaceuticals is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines for patients suffering from debilitating diseases with unmet medical need. Co.'s portfolio of assets include: ARCALYST® (rilonacept) is for the treatment of Cryopyrin-Associated Periodic Syndrome; mavrilimumab is targeting granulocyte-macrophage colony stimulating factor receptor alpha; vixarelimab is evaluating vixarelimab for the potential treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404 is a humanized monoclonal antibody that is designed to inhibit the CD40-CD154 interaction.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
128,310 |
194,896 |
224,296 |
274,612 |
| Total Sell Value |
$2,726,499 |
$3,969,036 |
$4,531,208 |
$5,316,305 |
| Total People Sold |
4 |
5 |
5 |
6 |
| Total Sell Transactions |
8 |
12 |
14 |
16 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Megna Michael R |
Chief Accounting Officer |
• – – |
2022-03-16 |
4 |
D |
$10.13 |
$2,725 |
D/D |
(269) |
3,930 |
|
- |
|
| Megna Michael R |
Chief Accounting Officer |
• – – |
2022-03-16 |
4 |
OE |
$0.00 |
$0 |
D/D |
775 |
4,199 |
|
- |
|
| Moat Ross |
Chief Commercial Officer |
• – – |
2022-01-15 |
4 |
A |
$9.63 |
$14,888 |
D/D |
1,546 |
5,891 |
|
- |
|
| Tessari Eben |
Chief Operating Officer |
• – – |
2022-01-15 |
4 |
A |
$9.63 |
$9,341 |
D/D |
970 |
107,780 |
|
- |
|
| Megna Michael R |
Chief Accounting Officer |
• – – |
2022-01-15 |
4 |
A |
$9.63 |
$6,288 |
D/D |
653 |
3,424 |
|
- |
|
| Moat Ross |
Chief Commercial Officer |
• – – |
2021-07-15 |
4 |
A |
$11.49 |
$11,065 |
D/D |
963 |
4,345 |
|
- |
|
| Tessari Eben |
Chief Operating Officer |
• – – |
2021-07-15 |
4 |
A |
$11.49 |
$9,973 |
D/D |
868 |
106,810 |
|
- |
|
| Megna Michael R |
Chief Accounting Officer |
• – – |
2021-07-15 |
4 |
A |
$11.49 |
$6,756 |
D/D |
588 |
2,771 |
|
- |
|
| Tessari Eben |
Chief Business OfficerOfficer |
• – – |
2021-06-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
105,942 |
|
-28% |
|
| Pano Arian |
Chief Clinical Dev. OfficerOff |
• – – |
2021-06-10 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
1,539 |
|
-28% |
|
| Moat Ross |
Group VP & Rilonacept GMOffice |
• – – |
2021-04-09 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
3,382 |
|
-32% |
|
| Patel Sanj K |
Chairman & CEO |
• • – |
2021-02-10 |
4 |
AS |
$23.07 |
$26,231 |
I/I |
(1,137) |
83,336 |
|
-35% |
|
| Patel Sanj K |
Chairman & CEO |
• • – |
2021-02-10 |
4 |
AS |
$23.06 |
$36,896 |
D/D |
(1,600) |
0 |
|
-35% |
|
| Patel Sanj K |
Chairman & CEO |
• • – |
2021-02-10 |
4 |
OE |
$1.59 |
$2,544 |
D/D |
1,600 |
1,600 |
|
- |
|
| Patel Sanj K |
Chairman & CEO |
• • – |
2021-02-09 |
4 |
AS |
$23.08 |
$543,973 |
I/I |
(23,569) |
84,473 |
|
-37% |
|
| Patel Sanj K |
Chairman & CEO |
• • – |
2021-02-09 |
4 |
AS |
$23.04 |
$470,039 |
D/D |
(20,401) |
0 |
|
-37% |
|
| Patel Sanj K |
Chairman & CEO |
• • – |
2021-02-09 |
4 |
OE |
$1.59 |
$32,438 |
D/D |
20,401 |
20,401 |
|
- |
|
| Patel Sanj K |
Chairman & CEO |
• • – |
2021-02-08 |
4 |
AS |
$23.00 |
$104,144 |
I/I |
(4,528) |
108,042 |
|
-35% |
|
| Patel Sanj K |
Chairman & CEO |
• • – |
2021-02-08 |
4 |
AS |
$23.00 |
$113,252 |
D/D |
(4,924) |
0 |
|
-35% |
|
| Patel Sanj K |
Chairman & CEO |
• • – |
2021-02-08 |
4 |
OE |
$1.59 |
$7,829 |
D/D |
4,924 |
4,924 |
|
- |
|
| Beetham Thomas W. |
EVP & Chief Legal Officer |
• – – |
2021-02-03 |
4 |
AS |
$22.09 |
$54,717 |
D/D |
(2,477) |
297,523 |
|
-31% |
|
| Beetham Thomas W. |
EVP & Chief Legal Officer |
• – – |
2021-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
300,000 |
300,000 |
|
- |
|
| Megna Michael R |
Chief Accounting Officer |
• – – |
2020-12-31 |
4 |
A |
$15.02 |
$6,083 |
D/D |
405 |
2,183 |
|
- |
|
| Rizvi Qasim |
Chief Commercial Officer |
• – – |
2020-12-31 |
4 |
D |
$17.67 |
$38,185 |
D/D |
(2,161) |
5,176 |
|
- |
|
| Rizvi Qasim |
Chief Commercial Officer |
• – – |
2020-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,337 |
7,337 |
|
- |
|
241 Records found
|
|
Page 8 of 10 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.05 (0.26%) 
